U.S. regulators rejected Elon Musk’s bid to test brain chips in humans, citing safety risks, per CNBC.
Such FDA rejections do not mean a company will ultimately fail to gain the agency’s human-testing approval. But it was rejected at least once in 2022, per Reuters.
"Innovation and safety are not an either-or scenario,” said Owen Faris, who helps oversee the FDA’s Office of Product Evaluation and Quality.
In Feb 9, the U.S. Department of Transportation said it was investigating Elon Musk's brain-implant company Neuralink over the potentially illegal movement of hazardous pathogens.
"We are conducting an investigation to ensure that Neuralink is in full compliance with federal regulations and keeping their workers and the public safe from potentially dangerous pathogens," the spokesperson said.
In December, Neuralink stated in six months, Musk's brain-chip-implant company plans to start implanting on humans.
Read more: https://unusualwhales.com/news/elon-musks-neuralink-plans-to-implant-coin-sized-chip-into-human-brains-in-six-months
U.S. regulators rejected Elon Musk’s bid to test brain chips in humans, citing safety risks
3/2/2023
FEATURED NEWS
Apple, AAPL, iPhone could triple in price to $3,500 if they’re made in the US
4/25/2025 Former U.S. Rep. George Santos sentenced to 7 years in prison for fraud
4/25/2025 One-third of younger millennials received down payment help in the form of a gift or a loan fro...
4/25/2025 China is considering suspending its 125% tariff on some US imports including medical equipment,...
4/25/2025
Stay Updated
Subscribe to our newsletter for the latest financial insights and news.
+With Unusual Whales
Get the best broker for options trading and earn Unusual Whales discounted! in cash with an eligible account deposit at tastytrade. Get an Unusual Whales bonus when you deposit $2000. Offer expires 3/31/25. Certain restrictions, terms and conditions apply.
Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.